Acumen Pharmaceuticals, Inc.
ABOS
$0.9801
-$0.0079-0.80%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 124.07M | 73.83M | 73.41M | 63.01M | 59.27M |
| Gross Profit | -124.07M | -73.83M | -73.41M | -63.01M | -59.27M |
| SG&A Expenses | 20.22M | 20.38M | 20.23M | 19.72M | 18.82M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 114.02M | 92.91M | 76.68M | 65.78M | 61.14M |
| Operating Income | -114.02M | -92.91M | -76.68M | -65.78M | -61.14M |
| Income Before Tax | -102.33M | -81.67M | -64.86M | -55.94M | -52.37M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -102.33 | -81.67 | -64.86 | -55.94 | -52.37 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -102.33M | -81.67M | -64.86M | -55.94M | -52.37M |
| EBIT | -114.02M | -92.91M | -76.68M | -65.78M | -61.14M |
| EBITDA | -113.95M | -92.84M | -76.62M | -65.71M | -61.08M |
| EPS Basic | -1.70 | -1.37 | -1.11 | -1.06 | -1.08 |
| Normalized Basic EPS | -1.07 | -0.86 | -0.70 | -0.66 | -0.68 |
| EPS Diluted | -1.70 | -1.37 | -1.11 | -1.06 | -1.08 |
| Normalized Diluted EPS | -1.07 | -0.86 | -0.70 | -0.66 | -0.68 |
| Average Basic Shares Outstanding | 240.05M | 237.98M | 232.13M | 213.08M | 194.29M |
| Average Diluted Shares Outstanding | 240.05M | 237.98M | 232.13M | 213.08M | 194.29M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
